Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Xetrane vs Imnovid in Healthy Male Subjects
NCT07694011Phase 1Completed
- Sponsor
- Knight Therapeutics Inc.
- Start
- Jan 2025
- Primary completion
- Feb 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pomalidomide in multiple myeloma (MM) (2 arms), sponsored by Knight Therapeutics Inc. Primary endpoints: Maximum Plasma Concentration and Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Quantifiable Concentration. Started Jan 2025; status: completed.
02
Drugs
pomalidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07694011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07694011.